Premium
FDA warns Alkermes about leaving overdose, other Vivitrol risks out of ads
Publication year - 2020
Publication title -
the brown university child and adolescent psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7567
pISSN - 1527-8395
DOI - 10.1002/cpu.30458
Subject(s) - food and drug administration , advertising , medicine , administration (probate law) , drug labeling , internet privacy , business , drug , medical emergency , pharmacology , political science , law , computer science
The Food and Drug Administration (FDA) has warned Alkermes for omitting warnings about serious risks of Vivitrol in a print ad for the medication. The warning was posted Dec. 11 on the FDA's website.